• Something wrong with this record ?

Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy

R. Bleach, SF. Madden, J. Hawley, S. Charmsaz, C. Selli, KM. Sheehan, LS. Young, AH. Sims, P. Souček, AD. Hill, M. McIlroy

. 2021 ; 27 (14) : 3980-3989. [pub] 20210520

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22019690

Grant support
MR/N022556/1 Medical Research Council - United Kingdom

PURPOSE: There is strong epidemiologic evidence indicating that estrogens may not be the sole steroid drivers of breast cancer. We hypothesize that abundant adrenal androgenic steroid precursors, acting via the androgen receptor (AR), promote an endocrine-resistant breast cancer phenotype. EXPERIMENTAL DESIGN: AR was evaluated in a primary breast cancer tissue microarray (n = 844). Androstenedione (4AD) levels were evaluated in serum samples (n = 42) from hormone receptor-positive, postmenopausal breast cancer. Levels of androgens, progesterone, and estradiol were quantified using LC/MS-MS in serum from age- and grade-matched recurrent and nonrecurrent patients (n = 6) before and after aromatase inhibitor (AI) therapy (>12 months). AR and estrogen receptor (ER) signaling pathway activities were analyzed in two independent AI-treated cohorts. RESULTS: AR protein expression was associated with favorable progression-free survival in the total population (Wilcoxon, P < 0.001). Pretherapy serum samples from breast cancer patients showed decreasing levels of 4AD with age only in the nonrecurrent group (P < 0.05). LC/MS-MS analysis of an AI-sensitive and AI-resistant cohort demonstrated the ability to detect altered levels of steroids in serum of patients before and after AI therapy. Transcriptional analysis showed an increased ratio of AR:ER signaling pathway activities in patients failing AI therapy (t test P < 0.05); furthermore, 4AD mediated gene changes associated with acquired AI resistance. CONCLUSIONS: This study highlights the importance of examining the therapeutic consequences of the steroid microenvironment and demonstrable receptor activation using indicative gene expression signatures.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019690
003      
CZ-PrNML
005      
20220804135915.0
007      
ta
008      
220720s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-20-4135 $2 doi
035    __
$a (PubMed)34016642
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bleach, Rachel $u Endocrine Oncology Research, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland $1 https://orcid.org/0000000160941644
245    10
$a Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy / $c R. Bleach, SF. Madden, J. Hawley, S. Charmsaz, C. Selli, KM. Sheehan, LS. Young, AH. Sims, P. Souček, AD. Hill, M. McIlroy
520    9_
$a PURPOSE: There is strong epidemiologic evidence indicating that estrogens may not be the sole steroid drivers of breast cancer. We hypothesize that abundant adrenal androgenic steroid precursors, acting via the androgen receptor (AR), promote an endocrine-resistant breast cancer phenotype. EXPERIMENTAL DESIGN: AR was evaluated in a primary breast cancer tissue microarray (n = 844). Androstenedione (4AD) levels were evaluated in serum samples (n = 42) from hormone receptor-positive, postmenopausal breast cancer. Levels of androgens, progesterone, and estradiol were quantified using LC/MS-MS in serum from age- and grade-matched recurrent and nonrecurrent patients (n = 6) before and after aromatase inhibitor (AI) therapy (>12 months). AR and estrogen receptor (ER) signaling pathway activities were analyzed in two independent AI-treated cohorts. RESULTS: AR protein expression was associated with favorable progression-free survival in the total population (Wilcoxon, P < 0.001). Pretherapy serum samples from breast cancer patients showed decreasing levels of 4AD with age only in the nonrecurrent group (P < 0.05). LC/MS-MS analysis of an AI-sensitive and AI-resistant cohort demonstrated the ability to detect altered levels of steroids in serum of patients before and after AI therapy. Transcriptional analysis showed an increased ratio of AR:ER signaling pathway activities in patients failing AI therapy (t test P < 0.05); furthermore, 4AD mediated gene changes associated with acquired AI resistance. CONCLUSIONS: This study highlights the importance of examining the therapeutic consequences of the steroid microenvironment and demonstrable receptor activation using indicative gene expression signatures.
650    _2
$a androstendion $x krev $x fyziologie $7 D000735
650    _2
$a inhibitory aromatasy $x terapeutické užití $7 D047072
650    _2
$a nádory prsu $x krev $x farmakoterapie $x etiologie $7 D001943
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a androgenní receptory $x fyziologie $7 D011944
650    _2
$a signální transdukce $7 D015398
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Madden, Stephen F $u Data Science Centre, RCSI University of Medicine and Health Sciences, Dublin, Ireland
700    1_
$a Hawley, James $u Department of Biochemistry, Manchester University, NHS Foundation Trust, London, United Kingdom
700    1_
$a Charmsaz, Sara $u Endocrine Oncology Research, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland $1 https://orcid.org/000000026003702X
700    1_
$a Selli, Cigdem $u Applied Bioinformatics of Cancer, Institute of Genetics and Cancer, University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom $1 https://orcid.org/0000000153308568
700    1_
$a Sheehan, Katherine M $u Department of Pathology, Beaumont Hospital, Dublin, Ireland
700    1_
$a Young, Leonie S $u Endocrine Oncology Research, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland
700    1_
$a Sims, Andrew H $u Applied Bioinformatics of Cancer, Institute of Genetics and Cancer, University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom $1 https://orcid.org/0000000190823665
700    1_
$a Souček, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Hill, Arnold D $u Endocrine Oncology Research, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland $u Department of Surgery, Beaumont Hospital, Dublin, Ireland
700    1_
$a McIlroy, Marie $u Endocrine Oncology Research, Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland. mmcilroy@rcsi.ie $1 https://orcid.org/0000000208278096
773    0_
$w MED00001121 $t Clinical cancer research : an official journal of the American Association for Cancer Research $x 1557-3265 $g Roč. 27, č. 14 (2021), s. 3980-3989
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34016642 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135908 $b ABA008
999    __
$a ok $b bmc $g 1823056 $s 1170933
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 14 $d 3980-3989 $e 20210520 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
GRA    __
$a MR/N022556/1 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options